MARKET

AWH

AWH

Aspira Womens Health Inc
NASDAQ
4.050
-0.070
-1.70%
Closed 16:00 02/27 EST
OPEN
4.230
PREV CLOSE
4.120
HIGH
4.300
LOW
3.940
VOLUME
27.14K
TURNOVER
0
52 WEEK HIGH
7.76
52 WEEK LOW
2.309
MARKET CAP
41.86M
P/E (TTM)
-1.9854
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at AWH last week (0219-0223)?
Weekly Report · 1d ago
First Lady Jill Biden Unveils $100M In Federal Funding To Support R&D - Watch Out for These Women Health Stocks
First Lady Jill Biden announced $100 million in federal funding for research and development for women's health. The initiative is part of the White House Initiative on Women's Health Research. The funding stems from the Advanced Research Projects Agency for Health in 2022. Biden highlighted the lack of research into women's issues as a concern.
Benzinga · 6d ago
Weekly Report: what happened at AWH last week (0212-0216)?
Weekly Report · 02/19 12:39
Weekly Report: what happened at AWH last week (0205-0209)?
Weekly Report · 02/12 12:23
Aspira Women’s Health Announces Late-Breaking Poster Presentation at the Upcoming 71st Annual Scientific Meeting for the Society for Reproductive Investigation (SRI)
Aspira Women’s Health Inc. Will present a late-breaking poster presentation at the Society for Reproductive Investigation in 2024. The company is focused on the development of gynecologic disease diagnostic tools. The poster will be presented in Vancouver, Canada on March 12-16, 2024.
Barchart · 02/12 07:00
Weekly Report: what happened at AWH last week (0129-0202)?
Weekly Report · 02/05 12:37
Weekly Report: what happened at AWH last week (0122-0126)?
Weekly Report · 01/29 12:18
Aspira Womens Health Inc: [Amend]Current report
Press release · 01/27 00:29
More
About AWH
Aspira Women's Health Inc. is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. Its products include Ova1, Overa, Ova1Plus and OvaWatch. Ova1 is a blood test intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician’s independent clinical and radiological evaluation does not indicate malignancy. Overa is a biomarker reflex intended to maintain Ova1's high sensitivity while improving specificity. Ova1Plus is a reflex offering, which uses Ova1 as the primary test and Overa as a confirmation for Ova1 intermediate range results. OvaWatch is a lab developed blood test intended to assist in the initial clinical assessment of malignancy risk in all women with an adnexal mass. The Company’s products are distributed through its own national sales force, through its decentralized testing platform.

Webull offers Aspira Women's Health Inc stock information, including NASDAQ: AWH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AWH stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AWH stock methods without spending real money on the virtual paper trading platform.